Pacific Edge Results for Six Months Ended 30 September 2021

Company Announcement
25 November 2021

PACIFIC EDGE RESULTS FOR SIX MONTHS ENDED 30 SEPTEMBER 2021
Pacific Edge reports continued strong revenue growth despite continuing impact of Covid-19

Unaudited results for the six months ended 30 September 2021 (1H22)
Summary of performance for the period (% changes compared to prior comparative period (pcp)):

• Total revenue increased 66% to $6.7m
• Operating revenue from test sales increased 62% to $5.4m
• Total Laboratory Throughput increased 62% to 11,136 tests
• Commercial Test volumes increased 64% to 9,192 tests
• Cash Receipts from Customers increased 110% to $5.4m
• Total operating expenses increased 41% on pcp to $15.7m
• Net Loss After Tax increased 27% to $9.0m
• Net cash, cash equivalents and short-term deposits were $91.6m (which excludes the $23.5m raised in the
Retail Offer completed in October 2021)
• Growth in the US sales force from 16 to 28 (+75%) and the addition of two new sales territories
• Publication of clinical evidence key to supporting use of multiple Cxbladder products and Pacific Edge’s
Patient In-Home Sampling System (PIHSS)
• Conducted successful $103.5m capital raise and dual listed on ASX
• Well positioned to capitalise on commercial milestones as Covid-19 restrictions ease, with a strong balance
sheet and scaled up operations in the U.S.

Cancer diagnostics business, Pacific Edge Limited (NZX/ASX: PEB) has reported continuing growth for the six months
ended 30 September 2021 (1H22), with key performance metrics significantly ahead of the same time last year,
driven by reimbursement milestones, increasing insurance coverage and adoption by urologists and healthcare
organisations.

CEO of Pacific Edge, David Darling, commented: “The momentum seen in 2H21 has continued with growth in test
volumes, sales and cash receipts. This is particularly pleasing given the resurgence in Covid-19 restrictions due to
the spread of the Delta variant, which further restricted access to clinics and urologists for both patients and for
our sales people in both the U.S. and New Zealand. As Covid-19 restrictions are lifted and access improves, we
expect to see a positive impact on our business.

“With a restructured balance sheet and significant cash resources now in hand, we continue to focus on scaling up
our commercial operations to accelerate our growth in the U.S. and other targeted markets. We continue to make
good progress as we position our Cxbladder suite of tests as the diagnostic product of choice for urologists and
patients. The clinical evidence supporting the outperformance of our products, growing endorsement by key
opinion leaders and our first mover advantage all serve to provide a strong competitive advantage for our business.”

In particular, the recent clinical papers published in the leading Journal of Urology, highlight a pivotal shift in clinical
utility from, firstly, an increase in clinical resolution from the combined use of multiple Cxbladder tests for each
patient presenting with haematuria and, secondly, the gain in clinical utility from Pacific Edge’s PIHSS for

Company Announcement
25 November 2021

management of patients outside the clinic. These publications are expected to provide added impetus to the
adoption of Cxbladder by urologists and healthcare organisations.

1H FY22 Financial Result Summary

Total Revenue increased 66% to $6.7m and Operating Revenue from Cxbladder sales increased 62% on the prior
comparative period (pcp) to $5.4m. This record result reflects the continued positive impact from the commercial
milestones achieved in 1H21, particularly LCD inclusion for Cxbladder Monitor and Cxbladder Triage from 1 July
2020 as well as growing adoption and use by urologists and healthcare organisations.

Total Laboratory Throughput (TLT) increased 62% on pcp and 24% on the prior six month period (2H FY21) to 11,136
tests.

Commercial test volumes increased 64% on pcp and 24% on the prior six month period (2H FY21) to 9,192 tests,
and accounted for 83% of TLT (up from 82% in FY21).

The U.S. market accounted for 81% of TLT, 81% of commercial test volumes and 93% of operating revenue. CMS
related tests (Medicare and Medicare Advantage) accounted for 65% of total U.S. commercial test volumes.
Cxbladder Detect and Cxbladder Monitor (the two Cxbladder tests included in the LCD) accounted for 95% of total
U.S. commercial test volumes.

Cash receipts from customers increased 110% on pcp to $5.4m, reflecting the positive impact of cash
reimbursement from the CMS and increased volumes.

Operating expenses increased 41% on pcp to $15.7m as the company invested for growth, and particularly the sales
and marketing efforts in the US.

For the six month period, Pacific Edge reported a Net Loss After Tax of $9.0m, an increase of 27% on pcp.

The recent capital raise of $103.5m has significantly strengthened the Company’s balance sheet. As at 30
September 2021, net cash, cash equivalents and short term deposits were $91.6m (which excludes the $23.5m
raised in the Retail Offer that was completed post-period end in October 2021).

Commercial Progress

The company continues to achieve commercial milestones as it progresses its global growth strategy. In particular,
in 1H22, Pacific Edge reported:

• Growth in the US sales force from 16 to 28 (75%) and the addition of two new sales territories
• Commercial adoption of second Cxbladder product (Cxbladder Triage) by Kaiser Permanente
• Expansion of coverage in New Zealand, with Northland and Taranaki public healthcare providers (DHBs)
adopting Cxbladder into use taking the total coverage to more than 70% of New Zealand’s population

Company Announcement
25 November 2021

• Acceptance of an important clinical paper outlining the significant increase in clinical resolution that can be
achieved from using multiple Cxbladder products in the evaluation of a patient presenting to the clinic with
haematuria
• Publication of real world lookback study in the U.S, highlighting the clinical utility of Cxbladder in a Covid19
setting for managing patients outside the clinic
• Analysis of results from Singapore study on-track for publication in early 2022. This will form the basis of
Pacific Edge’s planned commercial rollout in Southeast Asia, which is expected to become a market of scale
for Cxbladder over time similar to the U.S
• Dual listing on the ASX in September 2021
• Completion of successful $103.5 million capital raise to enable the company to capitalise on recent
commercial milestones and to accelerate the execution of its global growth strategy in markets of scale
• In October 2021, announced the appointment of new CEO, Dr Peter Meintjes, who will commence in the
role in January 2022.

Outlook

Pacific Edge has a positive outlook for FY22 and beyond and is well positioned to capitalise on the opportunities
available to the company.

The U.S. market remains the primary focus and continued growth is expected once Covid-19 restrictions ease. The
scaled up U.S. commercial operations provide the capacity and resource to drive growth opportunities and positive
results from this investment are now starting to be seen. The U.S. sales team grew to 28 experienced sales
representatives over the last year, with 30 sales reps expected to be operating by end-November.

The focus for FY22 is on growing the commercial adoption of Cxbladder by Kaiser Permanente and other large
healthcare organisations, further increasing reimbursement coverage from private payers, and achieving a positive
shift in guideline inclusion language following the publication of new clinical evidence further supporting the clinical
utility of Cxbladder.

Full integration into Kaiser’s patient referral system and Electronic Medical Records has yet to be concluded and
continues to constrain the growth rate expected from this important customer. Despite this, commercial test
numbers continue to grow.

The recent clinical papers supporting the combined use of multiple Cxbladder products will further evolve how
urothelial cancer is diagnosed and managed, with Cxbladder once again leading the way and delivering a greatly
enriched clinical proposition for urologists. These papers also provide additional support in favour of inclusion in
guidelines and national standards, which remains a key component that will drive widespread adoption of
Cxbladder.

Pacific Edge’s rest of world markets – New Zealand, Australia and Singapore – are markets of strategic importance,
with tailored plans being executed dependent on each market’s commercial maturity.

Chairman of Pacific Edge, Chris Gallaher, said: “Pacific Edge’s growth momentum over the last six months, despite
the ongoing headwinds from Covid19, confirms the validity of our global growth strategy and the way we go to
market. We have a committed and experienced team, with significant funding in place to allow us to scale up and
to deliver revenue growth and value creation for our shareholders in FY22 and beyond. We are confident in our

Company Announcement
25 November 2021

future and the actions we are taking now are positioning us to accelerate our growth trajectory once Covid-19
restrictions ease.”


ENDS

For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800

For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz


OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.

---

1H22 INTERIM
RESULTS PRESENTATION
FOR THE SIX MONTHS ENDED
30 SEPTEMBER 2021
25 November 2021

DISCLAIMER
Important Notice
This presentation has been prepared by Pacific Edge Limited (PEL) solely to provide interested parties with
further information about PEL and its activities at the date of this presentation.
Information of a general nature
The information in this presentation is of a general nature and does not purport to be complete nor does it
contain all the information which a prospective investor may require in evaluating a possible investment in
PEL or that would be required in a product disclosure statement, prospectus or other disclosure document
for the purposes of the New Zealand Financial Markets Conduct Act 2013 (FMCA) or the Australian
Corporations Act. PEL is subject to a disclosure obligation that requires it to notify certain material
information to NZX Limited (NZX) and ASX Limited (ASX) for the purpose of that information being made
available to participants in the market and that information can be found by visiting
www.nzx.com/companies/PEBand www2.asx.com.au/markets/company/PEB. This presentation should
be read in conjunction with PEL’s other periodic and continuous disclosure announcements released to
NZX and ASX.
Not an offer
This presentation is for information purposes only and is not an invitation or offer of securities for
subscription, purchase or sale in any jurisdictionwhere such offer purchase or sale would not be
permitted.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial product advice or investment advice or
a recommendation to acquire PEL securities, and has been prepared without taking into account the
objectives, financial situation or needs of investors. Before making an investment decision, prospective
investors should consider the appropriateness of the information having regard to their own objectives,
financial situation and needs and consult an NZX Firm, solicitor, accountant or other professional advisor if
necessary.
Forward-looking statements
This presentation contains forward-looking statements that reflect PEL’s current views with respect to
future events. Forward-looking statements, by their very nature, involve inherent risks and uncertainties.
Many of those risks and uncertainties are matters which are beyond PEL’s control and could cause actual
results to differ from those predicted. Variations could either be materially positive or materially negative.
The information is stated only as at the date of this presentation. Except as required by law or regulation
(including the NZX Listing Rules and ASX Listing Rules), PEL undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new information, future events or otherwise. To
the maximum extent permitted by law, the directors of PEL, PEL and any of its related bodies corporate
and affiliates, and their respective officers, partners, employees, agents, associates and advisers do not
make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of
such information, or the likelihood of fulfilment of any forward-looking statement or any event or results
expressed or implied in any forward-looking statement, and disclaim all responsibility and liability for
these forward-looking statements (including, without limitation, liability for negligence).
Financial data
All dollar values are in New Zealand dollars unless otherwise stated.
This presentation should be read in conjunction with, and subject to, the explanations and views of future
outlook on market conditions, earnings and activities given in the announcements relating to the results, and
interim report, for the six months ended 30 September 2021.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation
are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the
figures set out in this presentation.
Past performance
Investors should note that past performance, including past share price performance, cannot be relied upon as
an indicator of (and provides no guidance as to) future PEL performance, including future financial position or
share price performance.
Investment risk
An investment in securities of PEL is subject to investment risk and other known and unknown risks, some of
which are beyond the control of PEL. PEL does not guarantee any particular return or the performance of PEL.
Disclaimer
None of PEL or PEL’s advisers or any of their respective affiliates, related bodies corporate, directors, officers,
partners, employees and agents, have authorised, permitted or caused the issue, submission, dispatch or
provision of this presentation and, except to the extent referred to in this presentation, none of them makes or
purports to make any statement in this presentation and there is no statement in this presentation which is
based on any statement by any of them.
To the maximum extent permitted by law, none of PEL and its advisers, affiliates, related bodies corporate, nor
their respective directors, officers, partners, employees and agents makes any representation or warranty,
express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation;
and none of them shall have any liability (including for negligence) for:
•any errors or omissions in this presentation; or
•any failure to correct or update this presentation, or any other written or oral communications
provided in relation to this presentation; or
•any claim, loss or damage (whether foreseeable or not) arising from the use of any information in this
presentation or otherwise arising in connection with this presentation or the information contained
in it.
By receiving this presentation, you agree to the above terms and conditions.
2

1H22 KEY EVENTS
PLATFORM FOR
GROWTH
•Dual listing on the ASX in September 2021
•Successful $103.5 million capital raise
•Addition of new reputable global funds to the register
US COMMERCIAL
OPERATIONS
•Expansion of sales team by 75%; staffing of two new sales territories; increase in
support roles
•Adoption of second Cxbladder product (Cxbladder Triage) by Kaiser Permanente
NEW ZEALAND
•Two additional healthcare providers (DHBs) adopting Cxbladder into use
PIVOTAL CLINICAL
EVIDENCE
•Two pivotal papers highlighting significant clinical utility of Cxbladder –from
combined use of multiple Cxbladder products to evaluate haematuria patients;
and use of in home sampling system for managing patients outside of the clinic
•Analysis of results from Singapore study is underway with publication in early
2022 planned to trigger SEA commercial launch
3

POSITIVE MOMENTUM DESPITE
CONTINUING IMPACT OF COVID-19
•Resurgence of restrictions due to spread of
Delta variant in the US and New Zealand
•Sporadic access to clinics and urologists for
patients and for Pacific Edge sales team
•Health organisations priortisingresources
to cope with Covid-19
PACIFIC EDGE CONTINUES TO ADAPT AND GROW
IN THE CHALLENGING CONDITIONS:
•Virtual sales meetings and adaptation of sales
and marketing plans
•Continuing use and growing recognition of the
benefits of Cxbladder Patient In-Home
Sampling System (PIHSS)
•USA look-back study has highlighted the
significant clinical utility of Cxbladder PIHSS for
managing patients outside the clinic
4

1H22 COMMERCIAL PROGRESS
REIMBURSEMENT
•Positive step change compared to 1H21 reflects increasing adoption and
reimbursement from CMS from 1 July 2020
US REMAINS PRIMARY
MARKET
•US increasing as a percentage of test use and revenue. Expected to
grow further as US operations and sales team are scaled up
•30 sales reps will be ‘on the ground’ by end-November 2021, up from
16 employed for most of FY21
KAISER PERMANENTE (KP)
•Focus on integrating Cxbladder into KP’s electronic medical records to
facilitate the ‘User Experience’ and drive adoption internally. Progress
hampered as KP resources directed elsewhere during Covid-19
breakouts
PIVOTAL CLINICAL
EVIDENCE
•Two pivotal clinical papers highlighting the significant clinical utility
provided by Cxbladder. Will further evolve how urothelial cancer is
diagnosed and managed. Provides additional support in favour of
inclusion in guidelines and national standards
5

1H22 FINANCIAL SNAPSHOT
POSITIVE MOMENTUM DESPITE COVID RESTRICTIONS
NZ$m1H221H21% change
Total Revenue
6.74.1+66%
Operating Revenue(test sales)
5.43.3+62%
Operating Expenses
15.711.2+41%
Net Loss After Tax
9.07.1+27%
Cash Receipts from Customers
5.42.6+110%
Net Operating Cash Outflow
8.67.7+12%
Cash, cash equivalents and short term
deposits
91.6
1
29.3
1.Excludes proceeds of $23.5m from the Retail Offer component of the capital raising which was received 20 October 2021
6

6,864
8,950
11,136
0
2,000
4,000
6,000
8,000
10,000
12,000
1H212H211H22
NZ$’000
TOTAL LABORATORY
THROUGHPUT (TLT)
STRONG YEAR ON YEAR GROWTH IN TEST THROUGHPUT AND SALES
5,591
7,385
9,192
0
2,000
4,000
6,000
8,000
10,000
1H212H211H22
NZ$’000
COMMERCIAL TESTS
62% growth on 1H2164% growth on 1H21
7

8
TLT BY REGION
(6 months to 30 Sept 2021)
TLT BY TEST TYPE
(6 months to 30 Sept 2021)
TOTAL LABORATORY THROUGPUT
BY REGION AND TEST TYPE
US continues to grow in importance, up to 81% of
TLT and commercial tests
Growth in TLT for Cxbladder Detect, led by growth in
US test volumes (which are weighted towards Detect)
USA
1H22 : 81%
1H21 : 72%
ROW
1H22: 19%
1H21: 28%
Monitor
1H22: 25%
1H21: 24%
Triage
1H22: 19%
1H21: 27%
Detect
1H22: 56%
1H21: 49%
TLT: Total Laboratory Throughput. Includes all commercial and User Programmetests

STEP CHANGE IN REVENUE GROWTH AND CASH RECEIPTS
DRIVEN BY LCD INCLUSION, AND INCREASING REIMBURSEMENT AND ADOPTION
1.4
2.0
2.3
3.3
5.4
0.0
1.0
2.0
3.0
4.0
5.0
6.0
1H181H191H201H211H22
NZD Millions
OPERATING REVENUE
62% increase on 1H21
1.7
2.0
2.4
2.6
5.4
0.0
1.0
2.0
3.0
4.0
5.0
6.0
1H181H191H201H211H22
NZD Millions
CASH RECEIPTS
110% increase on 1H21
9

OPERATING EXPENSES
INCREASE IN OPERATING EXPENSES DRIVEN BY INVESTMENT IN GROWTH AND
ESCALATING TEST VOLUMES PROCESSED THROUGH THE LABORATORIES
10
(NZ$000)
HY22HY21% Change
Laboratory Operations
3,076 2,540 21%
Research
2,572 2,339 10%
Sales and Marketing
6,179 3,366 84%
General and Administration
3,888 2,908 34%
TOTAL
15,715 11,153 41%
•Laboratory expenses driven by volume
growth
•Research: Progress of clinical studies and
patient recruitment being hampered by
Covid-19
•Sales and Marketing driven by investment in
US sales team (sales reps increased from 16
for most of FY21 to 28 as at 30 Sept 21),
marketing and support costs.
•General and Administration uplift driven by
increased people capability to support growth
and ASX listing costs

USA REMAINS OUR PRIMARY MARKET
MOMENTUM IN US DESPITE COVID IMPACT
Scaled up U.S.
commercial
operations
provide capacity
and resource to
drive revenue
growth
11
USA
81% of TLT
81% of Commercial Tests
93% of Operating Revenue
Rest of World
19% of TLT
19% of Commercial Tests
7% of Operating Revenue
South East Asia
Australia
New Zealand

US GROWTH DRIVERS
•Strong growth in revenue and cash
receipts expected from CMS and Kaiser
Permanente once Covid-19 restrictions
ease
•Scaled up commercial operations with
30 sales reps covering 21 sales
territories will be operating by end-
November 2021 (up from 22 as at 31
March 2021)
•Sales focus is on growing the
commercial adoption of Cxbladderby
Kaiser Permanente and other large
healthcare institutions of scale, and
further increasing reimbursement
coverage from private payers
•U.S. commercial launch of the fourth
Cxbladder test (Cxbladder Resolve) to
be initiated with key customers
•Well positioned to capitalise on recent commercial milestones and
as Covid-19 restrictions ease
•US remains primary focus
•Recent clinical evidence supports adoption of multiple products and
Cxbladder PIHSS patient testing
•Publication of new clinical evidence will support additional US
guideline inclusion and greater adoption of Cxbladder
•Continued focus on adoption by remaining NZ public healthcare
providers, to take population coverage to 100%
•Southeast Asia has the potential to become a market of scale over
time with an accessible population base larger than the U.S
•Australia is in the early stages of commercial take-up -opportunity
to deliver sales and volume growth
•Appointment of new CEO, Dr Peter Meintjes(commencing January
2022)
POSITIVE GROWTH OUTLOOK
12

www.pacificedge.co.nz
www.cxbladder.com
www.pacificedgedx.com
P+64 3 479 5802
M+64 21 797981
Edavid.darling@pelnz.com
Enquiries to
David Darling
CEO
Pacific Edge Limited
13

GLOSSARY
•Commercial Tests arethose tests for which the Company is actively seeking reimbursement and cash
receipts, and tests performed at no charge in order to gain new customers.
•Total laboratory throughput (TLT) includes commercial tests and non-commercial tests related to customer’s
start-up User.
•CMS-Centersfor Medicare and Medicaid Services.
•Medicare–the federal health insurance programme for people who are 65 or older administered by the
CMS or CMS’s contractors
•Medicare Advantage –part of the Medicare programme. A type of Medicare health plan offered by
Medicare-approved private insurance companies, rather than the federal government. Often includes policy
advantages over the standard Medicare policy
14

---

CONSOLIDATED
INTERIM
FINANCIAL
STATEMENTS
FOR THE SIX MONTHS
ENDED 30 SEPTEMBER 2021

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
NOTES
UNAUDITED
SEPT 2021
6 MONTHS
($000)
UNAUDITED
SEPT 2020
6 MONTHS
($000)
AUDITED
MARCH 2021
12 MONTHS
($000)
REVENUE
Operating Revenue 4 5,378 3,326 7,701
Total Operating Revenue 5,378 3,326 7,701
Other Income4 747 558 2,386
Interest Income 108 173 351
Foreign Exchange Gain 497 3 1
Total Revenue and Other Income 6,730 4,060 10,439
OPERATING EXPENSES
Laboratory Operations3,076 2,540 5,466
Research2,572 2,339 4,584
Sales and Marketing6,179 3,366 9,202
General and Administration3,8882,908 5,410
Total Operating Expenses5 15,715 11,153 24,662
NET (LOSS) BEFORE TAX(8,985) (7,093) (14,223)
Income Tax Expense - - -
(LOSS) FOR THE PERIOD AFTER TAX(8,985) (7,093) (14,223)
Items that may be reclassified to profit or loss:
Translation of Foreign Operations - 14 46
TOTAL COMPREHENSIVE (LOSS) atttributable
to equity holders of the Company
(8,985) (7,079) (14,177)
Earnings per share for profit attributable to the
equity holders of the Company during the period
Basic and Diluted Earnings per share(0.012) (0.010) (0.020)
Consolidated Interim Financial Statements
Consolidated Statement of Comprehensive Income 3
Consolidated Statement of Changes in Equity 4
Consolidated Balance Sheet 6
Consolidated Statement of Cash Flows 7
Notes to the Consolidated Interim Financial Statements
1. Summary of Accounting Policies 8
2. Investment and Advances in Subsidiaries 9
3. Dividends 10
4. Revenue and Other Income 10
5. Operating Expenses 11
6. Segment Information 12
7. Share Capital 17
8. Reconciliation of Cash Used from Operating
Activities with Operating Net Loss 18
9. Contingent Liabilities 18
10. Unrecognised Revenue 18
11. Capital Commitments 19
12. Subsequent Event 19
13. The Impact of Covid-19 20
14. Related Parties 20
15. Net Tangible Assets 21
3 2

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
NOTES
SHARE
CAPITAL
ACCUMULATED
LOSSES
SHARE BASED
PAYMENTS
RESERVE
FOREIGN CURRENCY
TRANSLATION
RESERVE
TOTAL
EQUITY
($000)($000)($000)($000)($000)
UNAUDITED 6 MONTHS TO 30 SEPT 2020
Balance as at 31 March 2020 165,423 (156,242) 4,542 781 14,504
(Loss) After Tax - (7,093) - - (7,093)
Other Comprehensive Income - - - 14 14
TOTAL COMPREHENSIVE (LOSS) atttributable to equity holders of the Company - (7,093) - 14 (7,079)
Transactions with owners in their capacity as owners:
Issue of Share Capital7 21,968 - - - 21,968
Share Based Payments - Employee Remuneration7 284 - - - 284
Share Based Payments - Employee Share Options7 348 404 38 - 790
Balance as at 30 September 2020 188,023 (162,931) 4,580 795 30,467
UNAUDITED 6 MONTHS TO 30 SEPT 2021
Balance as at 31 March 2020 190,305 (170,061) 4,038 827 25,109
(Loss) After Tax - (8,985) - - (8,985)
Other Comprehensive Income - - - - -
TOTAL COMPREHENSIVE (LOSS) atttributable to equity holders of the Company - (8,985) - - (8,985)
Transactions with owners in their capacity as owners:
Issue of Share Capital7 76,045 - - - 76,045
Share Based Payments - Employee Remuneration7 172 - - - 172
Share Based Payments - Employee Share Options7 1,175 - (121) - 1,054
Balance as at 30 September 2021 267,697 (179,046) 3,917 827 93,395
AUDITED 12 MONTHS TO 31 MARCH 2021
Balance as at 31 March 2020 165,423 (156,242) 4,542 781 14,504
(Loss) After Tax - (14,223) - - (14,223)
Other Comprehensive Income - - - 46 46
TOTAL COMPREHENSIVE (LOSS) atttributable to equity holders of the Company - (14,223) - 46 (14,177)
Transactions with owners in their capacity as owners:
Issue of Share Capital7 21,962 - - - 21,962
Share Based Payments - Employee Remuneration7 284 - - - 284
Share Based Payments - Employee Share Options7 2,636 404 (504) - 2,536
Balance as at 31 March 2021 190,305 (170,061) 4,038 827 25,109
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements
5 4

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
For and on behalf of the Board of DirectorsDirector Director
Dated 24th day of November 2021
AS AT 30 SEPTEMBER 2021
CONSOLIDATED BALANCE SHEET
NOTES
UNAUDITED
SEPT 2021
6 MONTHS
UNAUDITED
SEPT 2020
6 MONTHS
AUDITED
MARCH 2021
12 MONTHS
($000)($000)($000)
CURRENT ASSETS
Cash and Cash Equivalents80,081 6,283 4,129
Short Term Deposits11,505 23,000 19,000
Receivables 2,978 1,656 2,866
Inventory 956 791 790
Other Assets930 760 557
Total Current Assets 96,450 32,490 27,342
NON-CURRENT ASSETS
Property, Plant and Equipment 908 664 688
Right of Use Assets 2,381 3,652 2,977
Intangible Assets 231 176 177
Total Non-Current Assets 3,520 4,492 3,842
TOTAL ASSETS 99,970 36,982 31,184
CURRENT LIABILITIES
Payables and Accruals 4,227 2,136 3,197
Borrowings - 803 -
Lease Liabilities 1,033 1,264 1,098
Total Current Liabilities 5,260 4,203 4,295
NON-CURRENT LIABILITIES
Lease Liabilities 1,315 2,312 1,780
Total Non-Current Liabilities 1,315 2,312 1,780
TOTAL LIABILITIES 6,575 6,515 6,075
NET ASSETS 93,395 30,467 25,109
Represented by:
EQUITY
Share Capital7 267,697 188,023 190,305
Accumulated Losses (179,046) (162,931) (170,061)
Share Based Payments Reserve 3,917 4,580 4,038
Foreign Translation Reserve 827 795 827
TOTAL EQUITY 93,395 30,467 25,109
FURTHER INFORMATION
Net Tangible Assets per share ($)15 0.118 0.042 0.034
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
CONSOLIDATED STATEMENT OF CASH FLOWS
NOTES
UNAUDITED
SEPT 2021
6 MONTHS
UNAUDITED
SEPT 2020
6 MONTHS
AUDITED
MARCH 2021
12 MONTHS
($000)($000)($000)
CASH FLOWS TO OPERATING ACTIVITIES
Cash was provided from:
Receipts from Customers 5,370 2,553 6,747
Receipts from Grant Providers 469 277 1,059
Interest Received 242 183 271
6,081 3,013 8,077
Cash was disbursed to:
Payments to Suppliers and Employees14,683 10,739 21,643
Net GST cash outflow (inflow) 14 (47) 4
14,697 10,692 21,647
Net Cash Flows (To) Operating Activities8(8,616) (7,679) (13,570)
NET CASH FLOWS FROM / (TO) INVESTING ACTIVITIES
Cash was provided from:
Proceeds from Short Term Deposits17,000 13,029 23,081
17,000 13,029 23,081
Cash was disbursed to:
Purchase of Short Term Deposits9,505 23,000 29,052
Capital Expenditure on Plant and Equipment 298 140 270
Capital Expenditure on Intangible Assets 108 42 108
9,911 23,182 29,430
Net Cash Flows From / (To) Investing Activities7,089 (10,153) (6,349)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash was received from:
Proceeds from Borrowings - 803 -
Ordinary Shares Issued7 80,000 22,204 22,000
Exercising of Share Options 657 - 1,500
80,657 23,007 23,500
Cash was disbursed to:
Repayment of Leases 575 654 1,250
Issue Expenses73,099 32 38
3,674 686 1,288
Net Cash Flows From Financing Activities76,983 22,321 22,212
Net Increase (Decrease) in Cash Held75,456 4,489 2,293
Add Opening Cash Brought Forward 4,129 1,755 1,755
Effect of exchange rate changes on net cash 496 39 81
Ending Cash Carried Forward80,081 6,283 4,129
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial StatementsNote: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements
7 6

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
1 . SUMMARY OF ACCOUNTING POLICIES
The unaudited consolidated interim financial statements (“Interim Financial Statements”)
presented are those of Pacific Edge Limited (“Company”) and its subsidiaries (“Group”).
The Company is registered and domiciled in New Zealand for the purpose of developing
and commercialising new diagnostic and prognostic tools for the early detection and
management of cancers. Pacific Edge Diagnostics New Zealand Limited and Pacific Edge
Diagnostics USA Limited manage and operate the laboratories used for the detection of
bladder cancer. Pacific Edge (Australia) Pty Limited’s purpose is to research and develop
the Cxbladder products and other prognostic tools. Pacific Edge Diagnostics Singapore
Pte Limited’s purpose is sales and marketing of bladder cancer products and assisting with
research and development. Pacific Edge Analytical Services Limited is a dormant entity.
The Company is a for profit entity, registered in New Zealand under the Companies Act
1993 and is a reporting entity for the purposes of the Financial Markets Conduct Act
2013. The Company is dual listed, with its primary listing of ordinary shares quoted in New
Zealand on the NZX Main Board, and a secondary listing in Australia as a Foreign Exempt
Entity on the ASX.
a) Basis of Preparation of Financial Statements
The Interim Financial Statements for the six months ended 30 September 2021 have
been prepared in accordance with New Zealand Generally Accepted Accounting Practice
(GAAP) and the Financial Markets Conduct Act 2013. They comply with the New Zealand
Equivalents to International Financial Reporting Standards (NZ IFRS) and other guidance
as issued by the External Reporting Board, as appropriate for profit entities, and with
International Financial Reporting Standards.
The Interim Financial Statements have been prepared in accordance with NZ IAS 34 -
Interim Financial Reporting. In complying with NZ IAS 34, these consolidated Interim
Financial Statements also comply with IAS 34 - Interim Financial Reporting and should
be read in conjunction with the Company’s 2021 Annual Report. The Interim Financial
Statements for the six months ended 30 September 2021 are unaudited. Comparative
balances for 30 September 2020 are unaudited, whilst the comparative balances for 31
March 2021 are audited.
The Interim Financial Statements are prepared on the basis of historical cost, except where
otherwise identified. The presentational currency used in the preparation of the financial
statements is New Zealand dollars and all values are rounded to the nearest thousand
dollars ($000).
b) Accounting Policies and Accounting Estimates
All significant accounting policies have been applied on a basis consistent with those used in
the audited financial statements of Pacific Edge Limited for the year ended 31 March 2021.
The Interim Financial Statements were authorised by the Board of Directors on 24th
November 2021. The Annual Financial Statements for the year ended 31 March 2021 were
authorised by the Board of Directors on 26th May 2021.
c) Audit
The Interim Financial Statements have not been audited. The comparative full year
financial results for the year ended 31 March 2021 have been audited.
d) Basis of Consolidation
The following entities and the basis of their inclusion for consolidation in these Interim
Financial Statements are as follows:
Ownership Interests
& Voting Rights
Name of Subsidiary
Place of
Incorporation
(or registration)
and Operation
Principal Activity
30 Sept
2021
(%)
30 Sept
2020
(%)
Pacific Edge Diagnostics
New Zealand Limited
New Zealand
Commercial Laboratory
Operation
100100
Pacific Edge (Australia)
Pty Limited
Australia
Biotechnology Research
& Development
100100
Pacific Edge Diagnostics
USA Limited
USA
Commercial Laboratory
Operation
100100
Pacific Edge Diagnostics
Singapore Pte Limited
Singapore
Commercial Sales
and Research &
Development
100100
Pacific Edge Analytical
Services Limited
New ZealandDormant Company100100
2. INVESTMENT AND ADVANCES IN SUBSIDIARIES
The consolidated Interim Financial Statements incorporate the assets and liabilities and
results of Pacific Edge Diagnostics New Zealand Limited, Pacific Edge (Australia) Pty
Limited, Pacific Edge Diagnostics USA Limited, Pacific Edge Diagnostics Singapore Pte
Limited and Pacific Edge Analytical Services Limited, all of which are 100% owned by the
Company.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
9 8

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
3. DIVIDENDS
The Company does not propose to pay dividends to shareholders similar to previous years.
This policy continues.
4. REVENUE AND OTHER INCOME
Unaudited
Sept 2021
6 Months
($000)
Unaudited
Sept 2020
6 Months
($000)
Audited
March 2021
12 Months
($000)
Cxbladder SalesCxbladder Sales
- US- US 4,982 4,982 2,906 2,906 6,888 6,888
- Rest of World- Rest of World 396 396 420 420 813 813
Total Operating Revenue Total Operating Revenue 5,378 5,378 3,326 3,326 7,701 7,701
Other IncomeOther Income
Grant RevenueGrant Revenue 295 295 - - 322 322
Research RebateResearch Rebate 452 255 952
Covid-19 SupportCovid-19 Support - - 303 1,112 1,112
Total Other IncomeTotal Other Income 747 747 558 558 2,386 2,386
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
5. OPERATING EXPENSES
The note below highlights total expenses shown within total operating expenses. These
items are then split across functions laboratory, research, sales and marketing and general
and administration as reported in the annual report.
Notes
Unaudited
Sept 2021
6 Months
($000)
Unaudited
Sept 2020
6 Months
($000)
Audited
March 2021
12 Months
($000)
Operating ExpensesOperating Expenses
AmortisationAmortisation 54 54 44 44 109 109
Auditors Remuneration*Auditors Remuneration*
- Group year end financial statements- Group year end financial statements 80 80 68 68 155 155
- Half year review of financial statements- Half year review of financial statements 27 29 29
- Foreign statutory financial statements 12 6 23
Total Auditors RemunerationTotal Auditors Remuneration119119103103207
Consultants and ContractorsConsultants and Contractors400355874
DepreciationDepreciation 127 106 188
Depreciation on Right of Use AssetsDepreciation on Right of Use Assets 526 569 1,073
Directors FeesDirectors Fees 186 186 151 151 278 278
Employee BenefitsEmployee Benefits 6,770 4,376 11,228
Employee Share Scheme ExpensesEmployee Share Scheme Expenses 172 172 284 284 284 284
Employee Share OptionsEmployee Share Options 397 397 585 585 1,036 1,036
Interest on Lease LiabilitiesInterest on Lease Liabilities 69 69 37 37 104 104
NZX / ASX / Registry FeesNZX / ASX / Registry Fees80664122
Rental and Lease ExpenseRental and Lease Expense 28 28 19 19 34 34
Other Operating ExpensesOther Operating Expenses6,061 4,460 9,125
Total Operating ExpensesTotal Operating Expenses 15,715 15,715 11,153 11,153 24,662 24,662
*In addition to the Auditors Remuneration in the Operating Expenses, NZ$42,000 was paid to PWC Australia for
the review of the proforma financials related to the ASX Listing and Capital Raise and has been included in Issue
Expenses within Share Capital.
Employee Share Scheme
Employee Share Scheme Expenses are a non-cash expense. These relate to shares issued
to employees in lieu of cash bonuses.
Employee Share Options
Employee Share Options are a non-cash expense. Refer to Note 8 of the Annual Report for
details of the accounting policy for Employee Share Schemes.

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTSNOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
11 10

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
Other Operating Expenses
The major categories of expenditure which make up operating expenses, but are not
disclosed separately above: Laboratory costs, Information Technology costs, Compliance
and Regulatory costs and Investor Relations costs.
6. SEGMENT INFORMATION
Operating segments are reported in a manner consistent with the internal reporting
provided to the chief operating decision-maker. The chief operating decision-maker,
who is responsible for allocating resources and assessing performance of the operating
segments, has been identified as the Chief Executive Officer who makes strategic
decisions.
There are two operating segments at balance date:
1. Commercial: The sales, marketing, laboratory and support operations to run the
commercial businesses worldwide.
2. Research: The research and development of diagnostic and prognostic products for
human cancer.
The reportable operating segment Commercial derives its revenue primarily from sales
of Cxbladder tests and the reportable operating segment Research derives its revenue
primarily from grant income. The Chief Executive Officer assesses the performance of the
operating segments based on net (loss) for the period.
Segment income, expenses and profitability are presented on a gross basis excluding
inter-segment eliminations to best represent the performance of each segment operating
as independent business units. The segment information provided to the Chief Executive
Officer for the reportable segment described above, for the six months ended
30 September 2021, is shown on the followng page.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
Unaudited 6 Months
to 30 September 2021
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
($000)
Income
Operating Revenue - External 5,378 - - 5,378
- Internal - - - -
Other Income 239 1,034 (526) 747
Interest Income 1 107 - 108
Foreign Exchange Gain-497 - 497
Total Income 5,618 1,638 (526) 6,730
Expenses
Expenses 9,137 6,396 (526) 15,007
Depreciation & Amortisation 481 227 - 708
Total Operating Expenses 9,618 6,623 (526) 15,715
Loss Before Tax (4,000)(4,985) - (8,985)
Income Tax Expense - - - -
Loss After Tax (4,000)(4,985) - (8,985)
Net Cash Flow to Operating Activities(3,393) (5,223) - (8,616)
Audited 12 Months
to 31 March 2021
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
($000)
Income
Operating Revenue - External 7,701 - - 7,701
- Internal - - - -
Other Income 1,224 2,130 (968) 2,386
Interest Income 1 350 - 351
Foreign Exchange Gain 3 (2) - 1
Total Income 8,929 2,478 (968) 10,439
Expenses
Expenses 14,529 9,730 (968) 23,291
Depreciation & Amortisation 934 437 - 1,371
Total Operating Expenses 15,463 10,167 (968) 24,662
Loss Before Tax (6,534) (7,689) - (14,223)
Income Tax Expense - - - -
Loss After Ta x (6,534) (7,689) - (14,223)
Net Cash Flow to Operating Activities (6,438) (7,132) - (13,570)
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTSNOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
13 12

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
Unaudited 6 Months
to 30 September 2020
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total
($000)
Income
Operating Revenue - External 3,326 - - 3,326
- Internal - - - -
Other Income 151 806 (399) 558
Interest Income - 173 - 173
Foreign Exchange Gain2 1 - 3
Total Income 3,479 980 (399) 4,060
Expenses
Expenses 5,866 4,967 (399) 10,434
Depreciation & Amortisation 503 216 - 719
Total Operating Expenses 6,369 5,183 (399) 11,153
Loss Before Tax(2,890) (4,203) - (7,093)
Income Tax Expense - - - -
Loss After Ta x (2,890) (4,203) - (7,093)
Net Cash Flow to Operating Activities (4,053) (3,626) - (7,679)
Eliminations
These are the intercompany transactions between the subsidiaries and the Parent.
These are eliminated on consolidation of Group results.
Total Laboratory Throughput
Unaudited
Commercial
(#tests)
Research
(#tests)
Total
(#tests)
Six months ended 30 September 2021 9,192 1,944 11,136
Twelve months ended 31 March 2021 12,976 2,838 15,814
Six months ended 30 September 2020 5,591 1,273 6,864
Laboratory Throughput is a key metric for the Group: Laboratory Throughput provides
evidence of the usage of Cxbladder products globally and the rates of adoption between
different customer segments. Total Laboratory Throughput includes commercial tests,
which are invoiced to customers, and research tests which are not considered to be
billable as these tests relate to user programs or other non-chargeable activities.
Commercial test numbers are also a key metric for the Group: Commercial Tests are those
tests for which the Company is actively seeking reimbursement and cash receipts, and
tests performed at no charge in order to gain new customers.

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
Segment Assets and Liabilities Information
Unaudited 6 Months to
30 September 2021
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 5,529 94,441 99,970
Total Liabilities 4,073 2,502 6,575
Audited 12 Months to
31 March 2021
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 5,477 25,707 31,184
Total Liabilities 4,529 1,546 6,075
As at 30 September 2020
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 5,805 31,177 36,982
Total Liabilities 4,895 1,620 6,515
Additions to non-current assets for the period include
Commercial
($000)
Research
($000)
Total
($000)
Property, Plant & Equipment 200 145 345
Right of Use Assets - - -
Intangible Assets 61 47 108
Total Additions to Non-Current Assets 261 192 453
The amounts provided to the Chief Executive Officer with respect to total assets and total
liabilities are measured in a manner consistent with that of the financial statements. These
assets and liabilities are allocated based on the operation of the segment and the physical
location of the asset.
There are no unallocated assets or liabilities.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTSNOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
15 14

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
Geographic Split of Revenue and Non-Current Assets
The Group generates most of the operating revenue from Commercial tests from the US
and New Zealand, and also receives other revenue from the US, Australia, Singapore and
New Zealand. Rest of World consists of Revenue from Australia and Singapore.
Unaudited
Sept 2021
6 Months
($000)
Unaudited
Sept 2020
6 Months
($000)
Audited
March 2021
12 Months
($000)
Operating and Other RevenueOperating and Other Revenue
USUS 4,982 4,982 2,906 2,906 7,677 7,677
New ZealandNew Zealand 915 585 2,133
Rest of WorldRest of World 228 228 394 394 277 277
Total Operating and Other RevenueTotal Operating and Other Revenue 6,125 6,125 3,884 3,884 10,087 10,087
The US accounted for 53% of non-current assets (September 2020: 60% and March 2021:
57%). Non-current assets located in New Zealand accounted for 47% of the Group’s total
(September 2020: 39% and March 2021: 42%) with Rest of World consisting of non-current
assets in Australia and Singapore, holding 0% of the Group’s total (September 2020: 1%
and March 2021: 1%).
Unaudited
Sept 2021
6 Months
($000)
Unaudited
Sept 2020
6 Months
($000)
Audited
March 2021
12 Months
($000)
Non-Current AssetsNon-Current Assets
USUS 1,866 1,866 2,702 2,702 2,201 2,201
New ZealandNew Zealand 1,649 1,736 1,618
Rest of WorldRest of World 5 5 54 54 23 23
Total Non-Current AssetsTotal Non-Current Assets 3,520 3,520 4,492 4,492 3,842 3,842
7. SHARE CAPITAL
Sept 2021
Shares
6 Months
Shares (000)
Unaudited
Sept 2021
6 Months
($000)
Unaudited
Sept 2020
6 Months
($000)
Audited
March 2021
12 Months
($000)
Opening Balance 727,779 190,305 165,423 165,423
Issue of Ordinary Shares - Placement
1
59,259 80,000 22,000 22,000
Issue of Ordinary Shares - Exercise of
Share Options
2
1,308 1,175 348 2,636
Issue of Ordinary Shares - Employee
Remuneration
3
123 172 284 284
Less: Issue Expenses - (3,955) (32) (38)
Movement 60,690 77,392 22,600 24,882
Closing Balance 788,469 267,697 188,023 190,305
1
During the period 59,259,259 shares were issued under placements at $1.35 per share. (September 2020 and
March 2021: 33,846,154 at $0.65)
2
During the period 1,307,501 share options were exercised at an average price of $0.50 per share (Six months to
September 2020: 619,999 at an average price of $0.33: Twelve months to March 2021: 3,635,835 at an average
price of $0.41)
3
During the period 123,086 shares were issued as part of employees remuneration in lieu of cash payments at an
average price of $1.40 per share. (Six months to September 2020 and Twelve months to March 2021: 645,182 at
$0.44)
There are 788,469,244 (September 2020: 724,763,562 and March 2021: 727,779,398)
ordinary shares on issue.
All fully paid shares in the Company have equal voting rights and equal rights to
dividends. All Ordinary Shares are fully paid and have no par value.
On the 23rd September 2021, the Group announced a capital raise to accelerate growth,
consisting of a Placement via an institutional bookbuild, which was to be followed by a
Retail Offer.
The Placement via the institutional bookbuild was successfully completed with settlement
occurring on the 29th and 30th September 2021. The Placement raised $80m of capital
at an issue price of $1.35. The Cash and Cash Equivalents and Short Term Deposits in the
Balance Sheet as at 30 September 2021 incorporates the proceeds of the Placement.
The Retail Offer was opened on the 28th September 2021, and closed on the 13th
October 2021. The Group raised a further $23.487m capital via the Retail Offer, with
17,389,099 shares allotted at $1.35 on the 20th October 2021. The proceeds of the Retail
Offer have not been included in the Balance Sheet as at 30 September 2021, and have
been included as a note in 12. Subsequent Events.

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTSNOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
17 16

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
8. RECONCILIATION OF CASH USED FROM OPERATING ACTIVITIES WITH
OPERATING NET LOSS
Unaudited
Sept 2021
6 Months
($000)
Unaudited
Sept 2020
6 Months
($000)
Audited
March 2021
12 Months
($000)
Net Loss for the Period (8,985) (7,093) (14,223)
Add Non Cash Items:
Depreciation 127 106 189
Loss on disposal of Property, Plant and Equipment - - 13
Amortisation 54 44 110
Employee Share Options 397 585 1,035
Employee bonuses paid in shares in lieu of cash 172 284 284
Depreciation on right of use assets 526 569 1,073
Interest on finance leases shown in lease repayments 69 37 103
Total Non Cash Items 1,345 1,625 2,807
Add Movements in Other Working Capital items:
(Increase) in Receivables and Other Assets (484) (1,081) (2,088)
(Increase) / Decrease in Inventory (166) 6 6
Increase/(Decrease) in Payables and Accruals172 (1,133) (71)
Effect of exchange rates on net cash (498) (3) (1)
Total Movement in Other Working Capital(976) (2,211) (2,154)
Net Cash Flows to Operating Activities(8,616)(7,679)(13,570)
9. CONTINGENT LIABILITIES
There were no known contingent liabilities at 30 September 2021 (March 2021: Nil and
September 2020: Nil). The Company and Group have not granted any securities in respect
of liabilities payable by any other party whatsoever.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
10. UNRECOGNISED REVENUE
Approximately 40% of Cxbladder tests performed by the Group in the US up to 30th June
2020 relate to patients covered by the Centers for Medicare and Medicaid Services (CMS).
The Group invoiced CMS for test performed for all patients with CMS coverage, however
no revenue from these tests has been recognised.
On 3rd July 2020 the Company received a positive coverage decision from CMS, which
results in the Company receiving reimbursement for all Cxbladder Monitor and Detect
tests performed after 1 July 2020 for patients covered by the (CMS) across the US that are
deemed medically necessary. Reimbursement for these tests is at the already determined
national CMS price for Cxbladder of US$760 per test.
The Company has commenced discussions with Novitas Solutions Inc who administer the
health insurance for the Centers for Medicare & Medicaid CMS seeking reimbursement for
tests performed prior to 30 June 2020 for patients covered by the CMS.
Tests performed prior to 30 June 2020 for CMS total 22,634.
No revenue has been recognised for these tests as they do not meet the definition of
revenue as per IFRS 15 - Revenue from Contracts with Customers, as there is no certainty
of any reimbursement on any of these tests performed prior to 30 June 2020, and
there is no ability to reliably estimate the level of consideration that would be received if
agreement can be reached with Novitas Solutions Inc over these previously performed
tests.
11. CAPITAL COMMITMENTS
There are no capital commitments at 30 September 2021 (September 2020: Nil and
March 2021: Nil).
12. SUBSEQUENT EVENTS
The Retail Offer of the capital raise detailed in Note 7. Share Capital was opened on the
28th September 2021, and closed on the 13th October 2021. The Group raised a further
$23.487m capital via the Retail Offer, with 17,389,099 shares allotted at $1.35 on the 20th
October 2021. Proceeds of the Retail Offer have not been included in the Balance Sheet as
at 30 September 2021.
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTSNOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
19 18

PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021PACIFIC EDGE LIMITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS 2021
13. THE IMPACT OF COVID-19
Covid-19 continues to have an impact on the throughput, revenue and expenses of the
Group. 
In the markets the Group operates in, measures have been employed by Governments in
an attempt to limit the spread of the virus. This has restricted the ability for people to visit
clinics and have tests performed for the occurrence of bladder cancer.  This resulted in
reduced throughput quantities for the group for the twelve months ended 31 March 2021.
While throughput quantities have increased in six months to 30 September 2021 (up 62%
on the prior corresponding six months ended 30 September 2020, and up 24% on the
previous six months ended 31 March 2021) the markets we operate in are still feeling the
effects of Covid-19, which is impacting the rate at which the Group can grow.
Offsetting the reduced access to urologists has been the increased adoption of the unique
in-home sampling system which allows patients to perform tests at home, with the results
provided to their urologist.
14. RELATED PARTIES
Details of all related party relationships have been disclosed in the annual report for
the year ended 31 March 2021. No significant new transactions with Directors or Key
Management Personnel occurred that would be considered a related party.
15. NET TANGIBLE ASSETS
Accounting Policy
Net Tangible Assets per share is a non-GAAP measure that is required to be disclosed by
the NZX Listing Rules. The calculation of the Group’s Net Tangible Assets per share and it’s
reconciliation to the consolidated balance sheet is presented below.
Unaudited
Sept 2021
6 Months
($000)
Unaudited
Sept 2020
6 Months
($000)
Audited
March 2021
12 Months
($000)
Total Assets99,970 36,982 31,184
Less Intangible Assets 231 176 177
Less Total Liabilities 6,575 6,515 6,075
Net Tangible Assets 93,164 30,291 24,932
Number of Shares Issued (000’s) 788,469 724,764 727,779
Net Tangible Assets per share $0.118 $0.042 $0.034
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2021
NOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTSNOTES TO THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS
21 20

87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
www.pacificedgedx.com

---

Template
Results announcement
(for Equity Security issuer/Equity and Debt Security issuer)
Updated as at 17 October 2019


Results for announcement to the market
Name of issuer Pacific Edge Limited
Reporting Period 6 months to 30 September 2021
Previous Reporting Period 6 months to 30 September 2020
Currency NZD
Amount (000s) Percentage change
Revenue from continuing
operations
Operating revenue $5,378
Other income $1,352
Operating revenue 62% increase
Other income 84% increase
Total Revenue $6,730 66%
Net profit/(loss) from
continuing operations
($8,985) 27% increase in loss
Total net profit/(loss) ($8,985) 27% increase in loss
Interim/Final Dividend
Amount per Quoted Equity
Security
The Company does not propose to pay dividends to
shareholders
Imputed amount per Quoted
Equity Security
Not applicable
Record Date Not applicable
Dividend Payment Date Not applicable
Current period Prior comparable period
Net tangible assets per
Quoted Equity Security
$0.118 $0.042
A brief explanation of any of
the figures above necessary
to enable the figures to be
understood
For commentary on the results, please refer to the commentary
in the released NZX release. Further information is also set out
in the unaudited financial statements of the Company for the 6
months to 30 September 2021 which accompany this
information.
Authority for this announcement
Name of person authorised
to make this announcement
Grant Gibson, Chief Financial Officer
Contact person for this
announcement
Grant Gibson
Contact phone number 03 479 8510
Contact email address grant.gibson@pelnz.com
Date of release through MAP 25 November 2021

Unaudited financial statements accompany this announcement.